2016_Head & Neck COURSE BOOK

Extreme trial

0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

|

| |

| |

CTX only Cetuximab + CTX

|

|

| |

HR (95%CI): 0.797 (0.644, 0.986) Strat. log-rank test: 0.0362

| |

|

|

10.1 mo

|

7.4 mo

|

|

| || ||| | || | | | | |||| || | | | | || || | | | || | | | || | | |

Survival Probability

| | | || | | | | || | | | | || || | | |

0.0

0

3

6

9

12

15

18

21

24

Survival Time [Months]

Patients at Risk CTX only CET + CTX 220 222

173 184

127 153

83 118

65 82

47 57

19 30

8

1 3

15

Vermorken et al, NEJM 2008